Head to Head Survey: Navidea Biopharmaceuticals (NYSE:NAVB) and Alpha Teknova (NASDAQ:TKNO)
Head to Head Survey: Navidea Biopharmaceuticals (NYSE:NAVB) and Alpha Teknova (NASDAQ:TKNO)
Alpha Teknova (NASDAQ:TKNO – Get Rating) and Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends.
Alpha Teknova（納斯達克股票代碼：TKNO — 獲取評級）和 Navidea Biopharmaceuticals（紐約證券交易所代碼：NAVB — 獲取評級）都是小型醫療公司，但哪家企業更好？我們將根據兩家公司的機構所有權實力、分析師建議、盈利能力、估值、收益、風險和股息對比這兩家公司。
Insider and Institutional Ownership
內部所有權和機構所有權
24.6% of Alpha Teknova shares are held by institutional investors. Comparatively, 5.6% of Navidea Biopharmaceuticals shares are held by institutional investors. 15.2% of Alpha Teknova shares are held by company insiders. Comparatively, 32.4% of Navidea Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Alpha Teknova的24.6％的股票由機構投資者持有。相比之下，Navidea Biopharmaceuticals的股票中有5.6％由機構投資者持有。15.2％的Alpha Teknova股票由公司內部人士持有。相比之下，Navidea Biopharmaceuticals的股份中有32.4％由公司內部人士持有。強大的機構所有權表明對沖基金、大型基金經理和捐贈機構認爲，從長遠來看，公司的表現將優於市場。
Risk & Volatility
風險與波動性
Alpha Teknova has a beta of -0.8, meaning that its share price is 180% less volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.
Alpha Teknova的beta值爲-0.8，這意味着其股價的波動性比標準普爾500指數低180％。相比之下，Navidea Biopharmaceuticals的beta值爲1.38，這意味着其股價的波動性比標準普爾500指數高38％。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| Alpha Teknova | -43.93% | -13.25% | -10.60% |
| Navidea Biopharmaceuticals | -2,209.23% | -517.32% | -222.49% |
| 淨利潤 | 股本回報率 | 資產回報率 | |
| 阿爾法·特克諾娃 | -43.93% | -13.25% | -10.60% |
| Navidea 生物製藥 | -2,209.23% | -517.32% | -222.49% |
Analyst Ratings
分析師評級
This is a summary of current ratings and recommmendations for Alpha Teknova and Navidea Biopharmaceuticals, as reported by MarketBeat.com.
據Marketbeat.com報道，這是Alpha Teknova和Navidea Biopharmaceuticals目前的評級和建議摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alpha Teknova | 0 | 0 | 2 | 0 | 3.00 |
| Navidea Biopharmaceuticals | 0 | 0 | 0 | 0 | N/A |
| 賣出評級 | 保持收視率 | 買入評級 | 強勁的買入評級 | 評分分數 | |
| 阿爾法·特克諾娃 | 0 | 0 | 2 | 0 | 3.00 |
| Navidea 生物製藥 | 0 | 0 | 0 | 0 | 不適用 |
Alpha Teknova currently has a consensus price target of $22.50, indicating a potential upside of 416.06%. Given Alpha Teknova's higher probable upside, equities analysts clearly believe Alpha Teknova is more favorable than Navidea Biopharmaceuticals.
Alpha Teknova目前的共識目標價爲22.50美元，表明潛在的上漲空間爲416.06％。鑑於Alpha Teknova可能有更高的上行空間，股票分析師顯然認爲Alpha Teknova比Navidea Biopharmaceuticals更有利。
Valuation and Earnings
估值和收益
This table compares Alpha Teknova and Navidea Biopharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
該表比較了Alpha Teknova和Navidea Biopharmaceuticals的收入、每股收益（EPS）和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alpha Teknova | $36.89 million | 3.32 | -$9.80 million | ($0.67) | -6.51 |
| Navidea Biopharmaceuticals | $530,000.00 | 16.84 | -$11.73 million | ($0.40) | -0.73 |
| 總收入 | 價格/銷售比率 | 淨收入 | 每股收益 | 市盈率 | |
| 阿爾法·特克諾娃 | 3689 萬美元 | 3.32 | -980 萬美元 | (0.67 美元) | -6.51 |
| Navidea 生物製藥 | 530,000.00 美元 | 16.84 | -1173 萬美元 | (0.40 美元) | -0.73 |
Alpha Teknova has higher revenue and earnings than Navidea Biopharmaceuticals. Alpha Teknova is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Alpha Teknova的收入和收益高於Navidea Biopharmaceuticals。Alpha Teknova的交易市盈率低於Navidea Biopharmaceuticals，這表明它目前是這兩隻股票中更實惠的一隻。
Summary
摘要
Alpha Teknova beats Navidea Biopharmaceuticals on 8 of the 13 factors compared between the two stocks.
Alpha Teknova在兩隻股票比較的13個因素中有8個擊敗了納威德亞生物製藥公司。
About Alpha Teknova
關於 Alpha Tekno
(Get Rating)
（獲取評分）
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
Alpha Teknova, Inc. 爲美國和國際上的生命科學市場提供關鍵試劑。其試劑可以發現、開發和生產生物製藥產品，例如藥物療法、新型疫苗和分子診斷。該公司提供用於細胞生長和克隆的預澆培養基板；用於細胞擴張的液體細胞培養基和補充劑；以及用於樣本處理、重懸和純化的分子生物學試劑。它爲生命科學市場提供服務，包括製藥和生物技術公司、合同開發和製造組織、體外診斷特許經營以及學術和政府研究機構。該公司成立於1996年，總部位於加利福尼亞州霍利斯特。
About Navidea Biopharmaceuticals
關於 Navidea Bioparmaceuticals
(Get Rating)
（獲取評分）
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
Navidea Biopharmaceuticals, Inc. 是一家生物製藥公司，專注於精準免疫診斷藥物和免疫療法的開發和商業化。它通過兩個部門運營，即診斷物質和治療開發計劃。該公司開發了 Manocept 平臺，用於靶向活化巨噬細胞上表達的 CD206 甘露糖受體，用於一系列診斷方式，包括單光子發射計算機斷層掃描、正電子發射斷層掃描 (PET)、伽瑪掃描、術中和/或光學熒光檢測，以及靶向巨噬細胞以及免疫和炎症相關疾病的治療化合物的輸送。它開發了 NAV3-31，已完成評估成像可重複性、可重複性和穩定性的 IIb 期臨床試驗，以及用於治療中度至重度類風溼關節炎 (RA) 患者的抗腫瘤壞死因子 α 療法的 tc99m tilmanocept 成像能力；NAV3-35 正在進行 RA 成像 IIb 期臨床試驗；NAV3-33，正處於 RA 成像 IIb 期臨床試驗；以及 NAV3-32，這是針對涉及 RA 的關節的 2b 期試驗。該公司還在開發用於心血管、卡波西肉瘤、結核病和其他免疫治療應用的tc99m tilmanocept。該公司前身爲Neoprobe Corporation，並於 2012 年 1 月更名爲 Navidea Biopharmaceuticals, Inc.Navidea Biopharmaceuticals, Inc. 成立於1983年，總部位於俄亥俄州都柏林。
Receive News & Ratings for Alpha Teknova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Teknova and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Alpha Teknova Daily 的新聞和 -在下面輸入您的電子郵件地址，即可通過Marketbeat.com的免費每日電子郵件時事通訊接收Alpha Teknova及相關公司的最新新聞和分析師評級的簡明每日摘要。